27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
In a report published Friday, MLV analyst George B. Zavoico initiated coverage on Pluristem Therapeutics (NASDAQ: PSTI) with a Buy rating and $4.50 price target.
In the report, MLV noted, “We are initiating coverage of Pluristem Therapeutics based on accumulating, though early, evidence of efficacy and safety of its proprietary cell therapy products advancing into later stage clinical trials this year and next. Moreover, the company's proprietary and cost-effective three-dimensional cell production system can supply cells for ongoing and planned clinical trials. In our view, the combination of a deep pipeline for multiple high value indications, ownership and control of producing its cell therapy product, and a secure financial position, distinguishes Pluristem from many of its competitors. With the company's stock trading in a narrow range for several months and with upcoming milestones, we think the company is approaching an inflection point. We are initiating coverage of Pluristem with a BUY recommendation and a $4.50 one-year price target.”
Pluristem Therapeutics closed on Thursday at $3.14.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!